A conference call featuring the management of NAMS is scheduled to take place on June 30 at 3 PM. The event will be hosted by Cantor Fitzgerald, and interested parties can access it via webcast. This call is anticipated to provide valuable insights into the company's performance and future strategies, offering investors crucial information.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for NewAmsterdam Pharma Co NV (NAMS, Financial) is $43.82 with a high estimate of $52.00 and a low estimate of $37.00. The average target implies an upside of 135.96% from the current price of $18.57. More detailed estimate data can be found on the NewAmsterdam Pharma Co NV (NAMS) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, NewAmsterdam Pharma Co NV's (NAMS, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
